ipharma tirzepatide south africa NICE recommends Lilly's for type 2 diabetes treatment All Products | Viva Aura

- Oral hypoglycemic agents, Insulin: the physician should consider that, in diabetic patients may alter their responsiveness to these drugs

Subcutaneous administration allows NAD+ Injections with NMN and 5-Amino-1MQ to enter circulation efficiently while providing a steady release of the compounds

Ideal candidates for weight loss injections may include: Individuals with a BMI over 30 or those struggling with obesity-related health issues

Tirzepatide is a new class of medication that can offer eligible people living with obesity another treatment option and potentially reduce the economic impact of obesity, which is estimated to cost the NHS 6.1 billion annually. This authorisation is based on results from the phase 3 SURMOUNT-1 and SURMOUNT-2 clinical trials, which both met their co-primary endpoints of demonstrating that tirzepatide 10mg and 15mg achieved superior mean percent change in body weight from baseline and greater percentage of participants achieving body weight reductions of at least 5% compared to placebo